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Background: Sarcopenic obesity (SO) is characterized by a combination of low muscle and 
high fat mass with an additive negative effect of both conditions on cardiometabolic risk. The 
aim of the study was to determine the effect of whole-body electromyostimulation (WB-EMS) 
on the metabolic syndrome (MetS) in community-dwelling women aged $70 years with SO.
Methods: The study was conducted in an ambulatory university setting. Seventy-five 
community-dwelling women aged $70 years with SO living in Northern Bavaria, Germany, were 
randomly allocated to either 6 months of WB-EMS application with (WB-EMS&P) or without 
(WB-EMS) dietary supplementation (150 kcal/day, 56% protein) or a non-training control group 
(CG). WB-EMS included one session of 20 min (85 Hz, 350 µs, 4 s of strain–4 s of rest) per 
week with moderate-to-high intensity. The primary study endpoint was the MetS Z-score with 
the components waist circumference (WC), mean arterial pressure (MAP), triglycerides, fasting 
plasma glucose, and high-density lipoprotein cholesterol (HDL-C); secondary study endpoints 
were changes in these determining variables.
Results: MetS Z-score decreased in both groups; however, changes compared with the CG 
were significant (P=0.001) in the WB-EMS&P group only. On analyzing the components of 
the MetS, significant positive effects for both WB-EMS groups (P#0.038) were identified for 
MAP, while the WB-EMS group significantly differed for WC (P=0.036), and the WB-EMS&P 
group significantly differed for HDL-C (P=0.006) from the CG. No significant differences were 
observed between the WB-EMS groups.
Conclusion: The study clearly confirms the favorable effect of WB-EMS application on the 
MetS in community-dwelling women aged $70 years with SO. However, protein-enriched 
supplements did not increase effects of WB-EMS alone. In summary, we considered this novel 
technology an effective and safe method to prevent cardiometabolic risk factors and diseases 
in older women unable or unwilling to exercise conventionally.
Keywords: sarcopenia, obesity, whole-body electromyostimulation, cardiovascular, metabolic 
risk, metabolic syndrome, community-dwelling, older people
Introduction
Sarcopenic obesity (SO), the combination of low muscle and high fat mass,1 is reported 
to be a frequent condition among women aged $70 years. According to Batsis et al2 
up to 94% of people aged $60 years can be classified as SO. SO is predominately 
caused by a decrease of physical activity (PA) in combination with stable caloric 
intake, malnutrition, and hormonal changes.3 Older people with SO demonstrated poor 
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health, reduced functional capacity, and quality of life right 
up to loss of independence and institutionalization.1 Besides 
the problem of progressive loss of muscle mass, the adjuvant 
accumulation of (intra-) abdominal fat in summary induces a 
higher risk for cardiometabolic diseases.4–7 Regular exercise 
favorably affected most risk factors and diseases in old age.8 
Resistance training may be an important factor not only to 
maintain muscle mass but also with respect to the preven-
tion and therapy of metabolic risk factors and disorders.9 
However, the majority of older people unfortunately do not 
fulfill the recommended exercise doses for positive impact 
on muscle mass, obesity, or other issues of cardiometabolic 
risk factors.10 For people who are unable or unwilling to 
exercise with the necessary amount and effort, whole-body 
electromyostimulation (WB-EMS) may be an option.11 
In fact, WB-EMS is time-efficient and less debilitating, 
thus producing higher acceptance among nonathletes.12 
Furthermore, WB-EMS has demonstrated positive effects 
on muscle and fat mass, and a gain of functional capacity 
in older sedentary people.13 However, even though there 
is some evidence that WB-EMS and WB-EMS-induced 
changes of body composition favorably decreased the 
metabolic syndrome (MetS) in older people,4,11 no study 
clearly addresses this issue. We consider this issue to be 
important for this cohort because the prevalence of the MetS 
is: a) increased among the elderly14 and b) subjects with SO 
are at a high risk for cardiometabolic diseases.15 Thus, the 
primary aim of this study was to determine the effect of 
WB-EMS on the MetS in women with SO. Additionally, 
we evaluate the effect of an adjuvant protein-rich diet in 
this cohort of older, inactive woman with low muscle and 
high fat mass.16
Our main hypothesis was that WB-EMS training sig-
nificantly affected the MetS as defined by the National 
Cholesterol Education Program Adult Treatment Panel III 
(NCEP ATP III) criteria17 in community-dwelling women 
with SO aged $70 years compared with a non-training, non- 
supplemented control group (CG). As our secondary hypothesis, 
we expected that additional protein supplement significantly 
increases the effect of WB-EMS on the MetS compared with 
WB-EMS application without supplementation.
Methods
Trial design
The FORMOsA-Sarcopenic Obesity Study (SOS) was a 
unicenter, controlled, semi-blinded trial with a parallel group 
design and three study arms, balanced randomization and 
stratification for age. The study is part of the Sarcopenia 
and Osteoporosis (FORMOsA) project and was partially 
supported by the “Bavarian Research Foundation”. The 
study was conducted between September 2013 and January 
2016 by the Institutes of Medical Physics and Biomedicine 
of Aging, University of Erlangen-Nürnberg (FAU), 
Germany. The University of Erlangen-Nürnberg Ethics 
Committee (Ethikantrag 301_13B) and the Federation 
Radiation Protection Agency (Bundesamt für Strahlenschutz, 
Z5-22462/2-2014-030) approved the study. After study start, 
no important changes in methods were made.
After detailed information, all study participants gave 
written informed consent. The FORMOsA-SOS trial was 
registered under www.ClinicalTrials.gov (NCT02356016). 
We strictly adhered to the CONSORT statement for the 
reporting of randomized controlled trials.
Participants
Sample size calculation refers to another primary study 
endpoint not presented here: appendicular skeletal muscle 
mass (ASMM) as the variable fraction of the skeletal muscle 
index (SMI: ASMM/[body height];² measured in kg/m2). 
In order to detect a difference of 300 g (standard deviation 
[SD]: 375 g) in ASMM between the WB-EMS and control 
groups, 25 participants/group were necessary to generate 
80% power and a two-sided significance level of 5%. The 
difference of 300 g is in agreement with recent results of a 
WB-EMS study in females aged $70 years.12
recruitment
Overall, 7,900 randomly selected women, aged $70 years, 
living independently in the Erlangen-Nürnberg area were 
contacted by letter using citizen registration records provided 
by the municipality. This letter listed the key study eligibility 
criteria. Of the 1,401 women who replied, 1,325 were invited 
and further checked for eligibility based on the following 
inclusion criteria: a) sarcopenia (SMI ,5.75 kg/m2)18 and 
b) obesity (.35% body fat).19 Exclusion criteria were: a) use 
of medication (eg, glucocorticoids, statins, active vitamin-D 
metabolites, anabolic steroids, and selective estrogen recep-
tor modulators), injuries or diseases (eg, Cushing syndrome, 
and other endocrine, neuronal, and metabolic myopathies) 
affecting muscle mass or preventing WB-EMS application 
(eg, TotalEndoProthesis; cardiac arrhythmia, renal insuf-
ficiency, cancer, and epilepsy); b) trained status (ie, exer-
cising .60 min/week); c) .4 weeks of absence during the 
interventional period; and d) alcohol abuse (ie, .40 g/d). 
Following our criteria, 101 community-dwelling women 
aged $70 years were eligible; 26 of the 101 eligible women 
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declined to participate mainly due to the randomization pro-
cess and the corresponding mandatory group allocation, but 
we nevertheless achieved our recruitment goal of 75 women 
(Figure 1). Recruitment and eligibility assessments were 
conducted between June and December 2014.
randomization procedures
Stratified for age (strata of 5 years), 75 participants were 
randomly assigned to three study arms: a) WB-EMS; 
b) WB-EMS and protein supplementation (WB-EMS&P); 
and c) non-training CG by a uniform allocation rate (1:1:1) 
(Figure 1). For allocation, lots were drawn by the participants. 
Each of the 75 lots were put in opaque plastic shells (“kinder 
egg,” Ferrero, Italy) and drawn from a bowl so that participants 
and researchers never knew the allocation beforehand.
Blinding
Research assistants/outcome assessors were blinded with 
respect to the status of the participants, ie, they were not 
informed or allowed to ask about participant status (WB-
EMS, WB-EMS&P, or CG).
Intervention
We set up three study groups. Two groups carried out 
26 weeks of the WB-EMS protocol, while the non-training 
CG was requested to maintain their habitual life style. Our 
setting was an ambulatory university setting, so all WB-EMS 
participants exercised at the Institute of Medical Physics, 
which is centrally located and can be easily reached by 
public transport. All the sessions were supervised by certi-
fied trainers who also logged the participants’ attendance. 
??????????????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????
??????????????????????????????????????? ???????????????????????????????????????? ??????????????????????????????????????? ?????????????????????????????????????????? ??????????????????????????????????????? ????????????? ??????????????????????????????????????????? ??????????????????????????? ?????? ????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????
?????????????????????????
???????????? ?????????????? ???????????????????
???????????? ??????????????
?????????????????????????????????????????????????????
???????????????????
?????????????????????????????????????????????????
• ????????????????????????????????????????????????
?????????????????????????????????????????????????
• ?????????????????
• ????????????????????????????????????????????????
?????????????????????????????????????????????????
• ?????????????????
• ??????????????
• ????????????????????????????????????????????????
?????? ?????????????????????????????????????????????
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??????????????????????????????????????????????????????????????????
Figure 1 Participant flow through the different study phases.
Abbreviations: FU, follow-up; sMI, skeletal muscle index; WB-eMs, whole-body electromyostimulation; WB-eMs&P, whole-body electromyostimulation and protein 
supplementation.
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The intervention was conducted between February and 
September 2015. Baseline characteristics of the three study 
groups are listed in Table 1.
WB-eMs intervention
WB-EMS equipment (miha bodytec®, Gersthofen, Germany) 
enables the simultaneous activation of up to 14–18 regions 
or 8–12 muscle groups (both upper legs, both upper arms, 
bottom, abdomen, chest, lower back, upper back, latissimus 
dorsi, and four free options; up to 2.800 cm2 stimulated area) 
with selectable intensity for each region. The latter includes 
the possibility to select and modify current intensity dur-
ing the WB-EMS session per individual and body region. 
In the present study, up to four participants simultaneously 
performed a video-guided WB-EMS program in a dorsal 
sitting/lying position (Figure 2) with slight movements of the 
lower and upper limbs once a week. Bipolar electric current 
was applied at a frequency of 85 Hz and an impulse width 
of 350 µs intermittently with 4 s of EMS-simulation using 
a direct impulse boost and 4 s of rest. Starting with 11 min 
of WB-EMS application, the length of the session was pro-
gressively increased to 20 min after 8 weeks; this duration 
was maintained for the rest of the training period. Due to 
body regions and individual disparities in current sensitivity, 
we were unable to prescribe the exact intensity (in mA). 
Thus, in order to generate a sufficient but tolerable intensity 
of the EMS application, participants were encouraged to 
exercise at a rate of perceived exertion (RPE) between 5 
and 6 (ie, “hard” to “hard+”) on the Borg 10-point Category 
Ratio Scale.20 In order to achieve this goal, the (current) 
intensity was individually adapted for each body region with 
the participants’ agreement during the first session and after 
6 and 12 weeks. The corresponding settings were saved for 
each muscle group/region in order to generate a fast, reliable, 
and valid setting in the subsequent sessions. From these initial 
settings, instructors slightly increased the (current) intensity 
every 3–5 min in close cooperation with the participants and 
thus maintained the prescribed RPE during the session.
Protein supplementation
The WB-EMS&P group was provided with nutritional 
supplement (FortiFit; Nutricia, Erlangen, Germany) with a 
high protein component. A standard portion of 40 g/day of 
the supplement represented a caloric value of 638 kJ and con-
tained 56% (21 g) of whey protein with a high l-leucin com-
ponent (2.8 g/portion), 10 g of carbohydrates (4.2 g sugar), 
3 g of fat (including 0.8 g of saturated fatty acids), 1.3 g of 
fiber, and a mixture of vitamins and minerals. We aimed to 
generate a total daily protein intake of at least 1.2 g/kg body 
mass/day in each WB-EMS&P participant.
Table 1 Baseline characteristics of the three study groups
Variable WB-EMS, MV ± SD WB-EMS&P, MV ± SD Control, MV ± SD P-value
Age (years) 77.3±4.9 76.4±2.9 77.4±4.9 0.289
Body mass index (kg/m2) 24.2±2.0 24.1±1.8 23.9±1.4 0.847
Fat free mass (kg) 39.4±42.9 39.9±2.4 38.8±3.1 0.523
Years menopausal (years) 50.1±5.8 49.9±6.0 49.7±5.9 0.908
Multi-morbid, na,b 18 22 21 0.319
hypertension, nb,c 17 19 19 0.777
hypercholesterolemia, nb,d,f 13 11 13 0.719
Diabetes mellitus type II, n 4 3 2 0.220
Physical activity (index)e 4.04±1.31 3.92±1.26 4.44±1.61 0.393
regular exercise 30–50 years, %f 8 12 12 0.647
llFDI (index)b 1.91±0.64 1.65±0.58 1.74±0.78 0.370
Fear of falling (index)g 1.28±0.27 1.22±0.18 1.21±0.34 0.663
gait speed (m/s) 1.14±0.14 1.17±0.19 1.23±0.23 0.280
hand grip strength (kg) 18.8±3.8 20.9±2.9 19.4±4.2 0.112
energy intake (MJ/day)h 7.11±0.89 7.32±0.69 6.97±0.95 0.388
Protein (g/day)h 72.4±18.6 70.6±17.3 72.7±18.1 0.919
Fat (g/day)h 65.9±11.4 68.6±10.3 61.7±7.9 0.082
Carbohydrates (g/day)h 179.4±33.5 175.9±37.4 172.2±28.3 0.768
Dietary vitamin D (IU/day)h 200±195 222±176 148±109 0.335
Notes: aTwo and more diseases using the disease cluster of schäfer et al;24 btotal cholesterol .250 mg/dl; cas assessed by PA questionnaire43 and interview. Index: scale from 
1 (very low) to 7 (very high); d$2 sessions/week from 20–50 years; elate life Function and Disability Instrument scale, from 1 (no problems) – 4 (great problems);44 fsystolic 
rr .140 or diastolic rr .90 mmhg; gFalls Efficacy Scale–International Version, scale from 1 (no concerns) – 4 (serious concerns);45 hbased on a 3-day dietary analysis.
Abbreviations: Cg, control group; llFDI, late-life Function and Disability Instrument; MJ, megajoule; PA, physical activity; WB-eMs, whole-body electromyostimulation; 
WB-EMS&P, whole-body electromyostimulation and protein supplementation; MV, mean value.
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nutritional counseling/vitamin D supplementation
Based on the baseline dietary records of the participant, 
a graduate nutritionist provided a 1-h group lecture and 
individual counseling for all participants of the WB-EMS&P 
group, with focus on the importance of protein intake. All 
participants were informed about the relevance of energy 
balance. Furthermore, all the women were provided with 
800 IE/day of vitamin D (cholecalciferol). Compliance with 
the vitamin D and dietary supplements prescription was 
monitored by monthly phone calls.
Outcomes
Primary outcome parameter
•	 Change of the MetS Z-score conformable to the NCEP 
ATP III criteria of the MetS17 from baseline to 26-week 
follow-up.
secondary outcome parameters
•	 Changes in variables determining the MetS from baseline 
to 26-week follow-up:
	 Waist circumference (WC)
	 Mean arterial pressure (MAP)
	 Triglycerides (TGs)
	 Fasting plasma glucose (FPG)
	 High-density lipoprotein cholesterol (HDL-C).
Assessments
Baseline and 6-month follow-up tests were consistently 
performed by the same research assistant at the same time 
of day (±1 h).
Body height and WC were determined using calibrated 
devices. Body mass and composition were determined via 
dual-energy X-ray absorptiometry (QDR 4500a; Hologic, 
Bedford, MA, USA).
The MetS, as defined in the NCEP ATP III criteria,17 
consists of five parameters: 1) increased WC ($88 cm in 
women; $102 cm in men); 2) increased blood pressure 
($130 mmHg systolic or $85 mmHg diastolic); 3) increased 
TGs ($150 mg/dL); 4) increased FPG ($110 mg/dL); and 
5) decreased HDL-C (#50 mg/dL in women). For the present 
study, we used the MetS Z-score according to Johnson et al.21 
The Z-score was calculated in the following way: ([50 – 
HDL-C]/SD – HDL-C) + ([TGs – 150]/SD – TGs) + ([FPG – 
100]/SD – FPG) + ([WC – 88]/SD – WC) + ([MAP – 100]/
SD – MAP). Negative Z-scores as well as negative Z-score 
changes can be considered as favorable.
After an overnight fast, blood was sampled in the morning 
in a sitting position from an antecubital vein. The serum sam-
ples were centrifuged at 3,000 RPM for 20 min and analyzed 
by the “Zentrallabor” of the Medical Department, University 
of Erlangen-Nürnberg. Glucose, HDL-C, and TGs (Olympus 
Diagnostica GmbH, Hamburg, Germany) were determined.
Blood pressure was determined in a lying position after 
10 min of rest with an automatic oscillometric device (Bosco; 
Bosch, Jungingen, Germany). All measurements were taken 
in a non-fasting condition. Participants were asked to avoid 
relevant PA 12 h before the tests and to refrain from coffee 
or tea for at least 2 h prior to testing. MAP was derived from 
systolic and diastolic pressures, weighted 1/3 systolic and 
2/3 diastolic.
Demographic parameters, pre-study PA and exercise 
levels, health risk factors, and quality of life parameters 
were sampled using the validated baseline questionnaires.22,23 
Follow-up questionnaires asked for changes in medication, 
Figure 2 WB-eMs application with slight movements in a supine sitting/lying position.
Abbreviation: WB-eMs, whole-body electromyostimulation.
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diseases, lifestyle, PA, exercise,24 dietary pattern, and 
nutritional supplementation, ie, parameters that may affect 
the study endpoints. Before and after the intervention phase, 
all participants kept a 3-day dietary record (two weekdays 
and one weekend day).25 From standard portions, all food 
items were converted to g/day and the foods were coded and 
analyzed for nutrient composition using the software EBI-
Spro version 11 for Windows (Erhard, Willstätt, Germany) 
including the “Bundeslebensmittelschlüssel” version 3.01.
statistical procedures
The intention to treat analysis included all participants who 
were randomly assigned to the study groups. R statistics 
software (R Development Core Team, Vienna, Austria) was 
used in combination with multiple imputation by Amelia II.26 
The full dataset was used for multiple imputations, with 
imputation being repeated 100 times. Amelia II confirmed 
that the multiple imputations worked well in all cases. Normal 
distribution of the primary and secondary outcomes presented 
in this contribution was statistically and graphically checked. 
Within-group changes were analyzed by dependent Student’s 
t-tests. In order to determine differences between the groups, 
one-way analysis of variance was applied using the approach 
of Allison27 to combine the results of the imputed datasets. 
In case of relevant differences, pairwise t-tests comparisons 
with pooled SD were conducted. In order to adjust for mul-
tiple testing P-values obtained in the pairwise comparisons, 
we used the method of Holm.28 All tests were two-tailed, 
significance was accepted at P,0.05 or adjusted at ,0.05.
Results
The percentage of patients lost to follow-up was 10% in the 
WB-EMS groups and 12% in the CG. Reasons for withdrawal 
are given in Figure 1. WB-EMS session attendance rate was 
high and did not significantly vary between the two groups 
(WB-EMS: 89%±6% vs WB-EMS&P: 88%±7%; P=0.453).
All participants of the WB-EMS&P group were fully 
compliant with the required dietary supplement intake, which 
was in accordance with our supplementation lists. Further-
more, all members said that they had taken the prescribed 
dose of 800 IE/day of vitamin D without interruption.
With respect to changes of parameters that may confound 
our results, we did not detect relevant variations within 
or between the groups. Lifestyle, PA, or exercise did not 
vary during the intervention period. Further, no participant 
reported worsening of diseases that may have confounded 
our primary results. However, four participants (WB-EMS: 
n=1; WB-WMS&P: n=2; CG: n=1) stated injuries that 
prevented WB-EMS and/or reduced habitual activity or 
exercise outside FORMOsA for longer than 2 weeks (with 
a maximum of 4 weeks).
Energy (-139±228 kcal, P=0.019) and protein intake 
(-0.07±0.21 g/kg/body mass/day, P=0.173) changed in the 
WB-EMS group only. However, due to the dietary supple-
ments, energy intake remained at pre-study level and each 
participant of the WB-EMS&P group obtained the prescribed 
protein intake of at least 1.20 g/kg body mass/day. Carbohy-
drates and fat intake remained stable in the WB-EMS and CG 
(P$0.799) and slightly decreased in the WB-EMS&P group 
(carbohydrates: 5.3%, P=0.306; fat: 7.6%, P=0.154). Dietary 
vitamin D intake did not change relevantly in the study groups 
(#3%; P=0.821) during the interventional period.
Finally, none of the participants complained about seri-
ous side effects, but one test person lost interest and finally 
quit because of a feeling of discomfort during WB-EMS 
application.
At baseline, 30% (WB-EMS&P) to 35% (WB-EMS) 
of this cohort of community-dwelling women aged $70 
years with SO suffered from MetS according to NCEP 
ATP-III. MetS Z-score significantly (P=0.001) improved in 
the WB-EMS&P group; however, the reduction among the 
WB-EMS group was less than expected and did not reach a 
statistically significant level (P=0.173) (Table 2). In paral-
lel, only the WB-EMS&P (P=0.007) but not the WB-EMS 
group (P=0.105) differed significantly from the CG that 
was slightly worse (P=0.324) (Table 2), so we deduce that 
WB-EMS training alone does not significantly improve the 
MetS (Z-score) in community-dwelling older woman, as 
we hypothesized. With respect to our secondary hypothesis, 
the difference between the two WB-EMS groups was not 
significant either (P=0.235), thus we have to revise this 
hypothesis too.
Table 2 Baseline values and changes of metabolic syndrome parameters in the three study groups
Variable WB-EMS, MV (± SD) WB-EMS&P, MV (± SD) CG, MV (± SD) P-value
Metabolic syndrome Z-score
Baseline -0.99 (±3.10) -0.59 (±3.19) -0.96 (±2.52) 0.871
Difference -0.36 (±1.30) -0.84 (±1.23) 0.26 (±1.32) 0.012
Abbreviations: Cg, control group; sD, standard deviation; WB-eMs, whole-body electromyostimulation; WB-eMs&P, whole-body electromyostimulation and protein 
supplementation; MV, mean value.
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Looking behind the constituting variables of the MetS 
Z-score we found significant differences. Baseline values, 
changes, and inter-group differences of selected parameters 
of the MetS Z-score are shown in Table 3. WC decreased in 
both WB-EMS groups (WB-EMS: -1.5%±2.3%, P=0.004; 
WB-EMS&P: 0.7%±1.6%, P=0.053) and was maintained in 
the CG (P=0.963). In parallel, MAP significantly decreased 
in both verum groups (WB-EMS: -8.1%±10.1% P=0.001 
and WB-EMS&P: -9.0%±8.9%; P#0.001) only. In the 
CG, HDL-C decreased significantly (6.6%±9.5%, P=0.007) 
with no significant changes in the WB-EMS (-1.8%±8.6%, 
P=0.373) or WB-EMS&P group (2.6%±10.7%, P=0.141). 
Slightly negative (CG, P=0.290), no (WB-EMS), or slightly 
favorable changes (P=0.301) were observed for TGs, while 
FPG non-significantly decreased (P.0.40) in all study 
groups. With respect to specific (pairwise) between-group 
differences, we did not determine significant results between 
the WB-EMS groups. In detail, both groups significantly 
differed from the CG for MAP (P#0.038); furthermore, the 
WB-EMS groups significantly varied for WC (P=0.036) and 
the WB-EMS&P group significantly differed for HDL-C 
(P=0.006) from the CG.
Discussion
The present study clearly confirmed our hypothesis of a favor-
able effect of WB-EMS-application on the MetS in this cohort 
of community-dwelling women aged $70 years with SO, 
though the effect was significant in the WB-EMS group with 
additional protein supplementation only. Although the latter 
finding did not clearly confirm our secondary hypothesis, we 
assumed that protein supplementation may have an additive 
effect to resistance type exercise with respect to the MetS. 
However, based on the present literature, this estimation was 
vague, although the effect of resistance training, which may be 
the type of exercise most prone to WB-EMS, with or without 
additional protein supplementation on cardiometabolic risk 
was very rarely addressed.29–31 After 12 weeks of resistance 
exercise with high volume and intensity, DeNysschen et al29 
did not report an effect of additional protein supplementa-
tion (either 26.6 g whey or 25.5 g soy protein/day compared 
with placebo) on (abdominal) body fat, serum lipids, and 
lipoproteins in their cohort of middle-aged hyperlipidemic, 
predominantly overweight men. Unfortunately, the sample 
size (n#10/subgroup) of this study may have been too low 
to generate adequate power to clearly address this issue. 
However, generating a more adequate statistical power, 
Kemmler et al30 demonstrated that 16 weeks of high-intensity 
resistance exercise with or without additional proteins (total 
protein intake: $1.5 g/kg body mass/day) did not result in 
significant group differences with respect to improvements 
of the MetS in a comparable male cohort. In parallel, after 
6 months of a predominantly resistance-type protocol con-
ducted with moderate volume and high intensity (80% of 
1 repetition maximum), Weinheimer et al31 did not demon-
strate a significant additional effect of whey protein (20, 40, 
or 60 g/day) on the MetS in middle-aged overweight to obese 
persons. However, the above-listed studies considerably 
vary from the sarcopenia status and the intervention of the 
older women of the present study; thus a direct comparison 
is difficult. Reducing the complexity of this issue, at least 
the positive effect of (whey) protein on cardiometabolic risk 
factors (ie, fat mass, hypertension, lipids and lipoproteins, 
and inflammatory markers) has been confirmed.32
Revisiting the primary hypothesis of the study, the fact 
that despite comparable high and significant effects on muscle 
mass in both WB-EMS groups, Kemmler et al33 suggested 
that the mechanism of WB-EMS effects on cardiometa-
bolic risk factors may not be necessarily muscle-induced. 
Indeed, the traditional belief of a generally beneficial effect 
of muscle tissue on cardiometabolic risk34 is vague. Even 
for glucose tolerance or insulin sensitivity in overweight 
and obese persons, recent findings by Kuk et al35 suggested 
that skeletal muscle mass per se is not associated with 
cardiometabolic parameters. Reductions of WC, which is 
considered a valid determinant of (intra-) abdominal fat,36,37 
Table 3 Baseline values and changes of selected parameters 
constituting the metabolic syndrome Z-score according to the 
nCeP ATP III criteria17
Variable WB-EMS,  
MV ± SD
WB-EMS&P,  
MV ± SD
CG,  
MV ± SD
P-value
Waist circumference (cm)
Baseline 93.5±4.78 92.8±7.24 91.4±6.41 0.474
Difference -1.43±2.11 -0.67±1.49 -0.02±2.26 0.066
Mean arterial pressure (mmhg)
Baseline 108.4±13.2 109.9±11.9 106.4±11.6 0.922
Difference -8.78±10.95 -9.94±9.83 -2.23±9.46 0.031
hDl-C (mg/dl)
Baseline 73.7±11.5 66.7±18.4 69.5±15.9 0.267
Difference -1.30±6.35 1.76±7.15 -4.58±6.58 0.016
Triglycerides (mg/dl)
Baseline 130.5±52.0 110.6±44.5 123.0±52.5 0.403
Difference 2.8±28.5 -2.6±36.0 9.8±39.2 0.507
Fasting glucose (mg/dl)
Baseline 95.9±16.7 99.1±19.0 96.1±12.4 0.922
Difference -3.0±10.3 -0.8±11.2 -3.6±7.9 0.640
Abbreviations: Cg, control group; hDl-C, high-density lipoprotein cholesterol; 
nCeP ATP III, national Cholesterol education Program Adult Treatment Panel III; 
sD, standard deviation; WB-eMs, whole-body electromyostimulation; WB-eMs&P, 
whole-body electromyostimulation and protein supplementation; MV, mean value.
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a parameter closely related to MetS,35,38,39 was also com-
parable between the WB-EMS groups, thus this parameter 
cannot be mentioned for the lack of significant effects of 
isolated WB-EMS on the MetS. In summary, we conclude 
that there is a minor additive effect of protein to resistance 
exercise that contributes to the results presented here.
Some limitations of the study have to be addressed to 
allow the reader to estimate the generalizability, applicabil-
ity, and relevance of our results.
(a) The use of a MetS Z-score that summarizes the mul-
tiple aspects of the cardiometabolic risk may be irritating 
at first; however, creating a continuous score is much more 
sensitive to changes than to evaluate the prevalence of the 
MetS per se or the number of prevalent MetS risk factors.21 
A limitation of the MetS calculation is that all parameters 
were equally weighted, although some parameters might 
have a bigger impact on the development of cardiometabolic 
diseases than others. (b) One may argue that the statistical 
power of the study was too low to address the MetS, because 
our sample size calculation was based on the ASMM as 
the more critical endpoint with respect to an intervention 
that focuses on women with SO. However, a recent study 
addressed a high intensity training resistance training 
protocol, ie, an exercise method very close to a WB-EMS 
intervention,40 indicating that the sample size calculated for 
ASMM (n=25 per group) was sufficient to address the MetS 
in parallel. However, we have to admit that the power to 
evaluate the presumably less prominent effect of additional 
(to WB-EMS) protein supplements on the MetS (and on 
ASMM) may have been indeed too low. We were aware of 
this problem; however, in stark contrast to the data reported 
by Batsis et al2 and even when focussing on the SMI16 as the 
sole sarcopenia criteria (which may also be considered as a 
study limitation), the prevalence of sarcopenia in community-
dwelling older women is rare, at least in Germany.41 Also, 
bearing in mind the additional obesity criteria and the factor 
that this cohort is hard to convince to exercise frequently, 
we were finally contended to even generate the estimated 
sample size of 25 eligible women/group (out of n=1,325), 
necessary to address the effect of our primary hypothesis. In 
summary, we consider the additional protein issue more as 
an experimental hypothesis with a pilot study character. (c) 
With respect to the intervention, the WB-EMS application 
in a lying/sitting supine position 20 min once a week may 
have been too gentle, at least considering the unexpected 
high physical fitness level of the cohort (Table 1). In parallel, 
average protein intake at baseline was unexpectedly high in 
all groups (Table 1). Our protocol scheduled a daily protein 
supplementation of .1.2–,1.4 g/kg body mass/day for the 
WB-EMS&P group, which may be too close to the 1.0–1.1 g/
kg/day of the dietary protein intake of the non-supplemented 
groups (WB-EMS and CG) to generate a relevant effect.
Conclusion
Although our result might not be generalizable across all 
cohorts with sarcopenia or SO, it indicates at least the general 
effectiveness, safety, attractiveness, and feasibility of WB-
EMS. However, taking into account the lower strain threshold 
of institutionalized women, we speculatively expected higher 
effects compared with our multimorbid but unexpectedly fit 
community dwelling cohort. Addressing the relevance of 
WB-EMS in older people with unfavorable body composi-
tion and functional limitation, we conclude that multimodal 
exercise protocol with endurance, resistance, and coordina-
tion would be definitely superior to WB-EMS application. 
However, as a matter of fact, the majority of older people are 
either no more capable or/and unexperienced to participate 
in intense and time-consuming exercise protocols.42 Thus, 
the take home message of this article is that WB-EMS can 
be considered as an appropriate training option for people 
unable or unwilling to exercise conventionally.
Acknowledgments
The authors would like to thank the “Bayerische Forsc-
hungsstiftung” (Munich, Germany) for supporting the 
FORMOsA project. They further acknowledge the support 
of miha-bodytec (Gersthofen, Germany), Nutricia (Erlangen, 
Germany), and physiomed (Leipersdorf, Germany).
The present work was performed in fulfillment of the 
requirements for obtaining the degree “Dr. med.”
Disclosure
The authors report no conflicts of interest in this work.
References
1. Stenholm S, Harris TB, Rantanen T, Visser M, Kritchevsky SB, 
Ferrucci L. Sarcopenic obesity: definition, cause and consequences. Curr 
Opin Clin Nutr Metab Care. 2008;11(6):693–700.
2. Batsis JA, Barre LK, Mackenzie TA, Pratt SI, Lopez-Jimenez F, Bartels SJ. 
Variation in the prevalence of sarcopenia and sarcopenic obesity in older 
adults associated with different research definitions: dual-energy X-ray 
absorptiometry data from the national health and nutrition examination 
survey 1999–2004. J Am Geriatr Soc. 2013;61(6):974–980.
3. Dominguez LJ, Barbagallo M. The cardiometabolic syndrome and 
sarcopenic obesity in older persons. J Cardiometab Syndr. 2007;2(3): 
183–189.
4. Kim SH, Chung JH, Song SW, Jung WS, Lee YA, Kim HN. Rela-
tionship between deep subcutaneous abdominal adipose tissue and 
metabolic syndrome: a case control study. Diabetol Metab Syndr. 2016; 
8:10.
 
Cl
in
ica
l I
nt
er
ve
nt
io
ns
 in
 A
gi
ng
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
2.
18
7.
19
5.
17
 o
n 
20
-J
ul
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical Interventions in Aging 2016:11 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1705
Whole body electromyostimulation and the metabolic syndrome
 5. Lee J, Hong YP, Shin HJ, Lee W. Associations of sarcopenia and sarcopenic 
obesity with metabolic syndrome considering both muscle mass and 
muscle strength. J Prev Med Public Health. 2016;49(1):35–44.
 6. Klip A, Paquet MR. Glucose transport and glucose transporters in muscle 
and their metabolic regulation. Diabetes Care. 1990;13(3):228–243.
 7. Reaven GM. Banting lecture 1988. Role of insulin resistance in human 
disease. Diabetes. 1988;37(12):1595–1607.
 8. Cornelissen VA, Fagard RH, Coeckelberghs E, Vanhees L. Impact 
of resistance training on blood pressure and other cardiovascular risk 
factors: a meta-analysis of randomized, controlled trials. Hypertension. 
2011;58(5):950–958.
 9. Strasser B, Schobersberger W. Evidence for resistance training as a 
treatment therapy in obesity. J Obes. 2011;2011.pii:482564.
 10. Chodzko-Zajko WJ, Proctor DN, Fiatarone Singh MA, et al. American 
College of Sports Medicine position stand. Exercise and physical activ-
ity for older adults. Med Sci Sports Exerc. 2009;41(7):1510–1530.
 11. Kemmler W, Bebenek M, Engelke K, von Stengel S. Impact of whole-
body electromyostimulation on body composition in elderly women 
at risk for sarcopenia: the Training and ElectroStimulation Trial 
(TEST-III). Age (Dordr). 2014;36(1):395–406.
 12. Kemmler W, von Stengel S. Whole-body electromyostimulation as a 
means to impact muscle mass and abdominal body fat in lean, sedentary, 
older female adults: subanalysis of the TEST-III trial. Clin Interv Aging. 
2013;8:1353–1364.
 13. Kemmler W, Schliffka R, Mayhew JL, von Stengel S. Effects of whole-
body electromyostimulation on resting metabolic rate, body composi-
tion, and maximum strength in postmenopausal women: the training and 
electrostimulation trial. J Strength Cond Res. 2010;24(7):1880–1887.
 14. De Luis DA, Lopez Mongil R, Gonzalez Sagrado M, Lopez Trigo JA, 
Mora PF, Castrodeza Sanz J; Group Novomet. Prevalence of metabolic 
syndrome with International Diabetes Federation Criteria and ATP III 
Program in patients 65 years of age or older. J Nutr Health Aging. 2010; 
14(5):400–404.
 15. Lu CW, Yang KC, Chang HH, Lee LT, Chen CY, Huang KC. Sarcopenic 
obesity is closely associated with metabolic syndrome. Obes Res Clin 
Pract. 2013;7(4):e301–e307.
 16. Goisser S, Kemmler W, Porzel S, et al. Sarcopenic obesity and complex 
interventions with nutrition and exercise in community-dwelling older 
persons – a narrative review. Clin Interv Aging. 2015;10:1267–1282.
 17. Executive summary of the third report of The National Cholesterol 
Education Program (NCEP) expert panel on detection, evaluation, and 
treatment of high blood cholesterol in adults (Adult Treatment Panel III). 
JAMA. 2001;285(19):2486–2497.
 18. Janssen I, Baumgartner RN, Ross R, Rosenberg IH, Roubenoff R. Skel-
etal muscle cutpoints associated with elevated physical disability risk 
in older men and women. Am J Epidemiol. 2004;159(4):413–421.
 19. Physical status: the use and interpretation of anthropometry. Report of a 
WHO expert committee. World Health Organ Tech Rep Ser. 1995;854: 
1–452.
 20. Borg E, Kaijser L. A comparison between three rating scales for per-
ceived exertion and two different work tests. Scand J Med Sci Sports. 
2006;16(1):57–69.
 21. Johnson JL, Slentz CA, Houmard JA, et al. Exercise training amount 
and intensity effects on metabolic syndrome (from Studies of a Targeted 
Risk Reduction Intervention through Defined Exercise). Am J Cardiol. 
2007;100(12):1759–1766.
 22. Kemmler W, Riedel H. Körperliche Belastung und Osteoporose – Einfluß 
einer 10monatigen Interventionsmaßnahme auf ossäre und extraossäre 
Risikofaktoren einer Osteoporose. Dtsch Z Sportmed. 1998;49(9): 
270–277.
 23. Fahrenberg J, Myrtek M, Wilk D, Kreutel K. [Multimodal assessment 
of life satisfaction: a study of patients with cardiovascular diseases]. 
Psychother Psychosom Med Psychol. 1986;36(11):347–354.
 24. Kemmler W, Weineck J, Kalender WA, Engelke K. The effect of habitual 
physical activity, non-athletic exercise, muscle strength, and VO2max on 
bone mineral density is rather low in early postmenopausal osteopenic 
women. J Musculoskelet Neuronal Interact. 2004;4(3):325–334.
 25. Volkert D, Kreuel K, Heseker H, Stehle P. Energy and nutrient intake 
of young-old, old-old and very-old elderly in Germany. Eur J Clin Nutr. 
2004;58(8):1190–1200.
 26. Honaker J, King G, Blackwell M. Amelia II: a program for missing 
data. JSS. 2011;45:1–47.
 27. Alison P. Missing Data. Thousand Oaks, CA: Sage Publication; 2002.
 28. Holm S. A simple sequentially rejective multiple test procedure. Scand 
J Stat. 1979;6:65–70.
 29. Denysschen CA, Burton HW, Horvath PJ, Leddy JJ, Browne RW. Resis-
tance training with soy vs whey protein supplements in hyperlipidemic 
males. J Int Soc Sports Nutr. 2009;6:8.
 30. Kemmler W, Wittke A, Bebenek M, Frohlich M, von Stengel S. 
High intensity resistance training methods with and without protein 
supplementation to fight cardiometabolic risk in middle-aged 
males: a randomized controlled trial. Biomed Res Int. 2016;2016: 
9705287.
 31. Weinheimer EM, Conley TB, Kobza VM, et al. Whey protein supple-
mentation does not affect exercise training-induced changes in body 
composition and indices of metabolic syndrome in middle-aged over-
weight and obese adults. J Nutr. 2012;142(8):1532–1539.
 32. Pal S, Radavelli-Bagatini S. The effects of whey protein on cardiometa-
bolic risk factors. Obes Rev. 2013;14(4):324–343.
 33. Kemmler W, Teschler M, Weissenfels A, et al. Whole-body Electro-
myostimulation to fight sarcopenic obesity in community-dwelling 
older women at risk. Results of the randomized controlled FORMOsA-
sarcopenic obesity study. Osteoporos Int. 2016;27(10):3261–3270.
 34. Bayol SA, Bruce CR, Wadley GD. Growing healthy muscles to opti-
mise metabolic health into adult life. J Dev Orig Health Dis. 2014; 
5(6):420–434.
 35. Kuk JL, Kilpatrick K, Davidson LE, Hudson R, Ross R. Whole-body 
skeletal muscle mass is not related to glucose tolerance or insulin sen-
sitivity in overweight and obese men and women. Appl Physiol Nutr 
Metab. 2008;33(4):769–774.
 36. Kamel EG, McNeill G, Van Wijk MC. Usefulness of anthropometry 
and DXA in predicting intra-abdominal fat in obese men and women. 
Obes Res. 2000;8(1):36–42.
 37. Despres JP, Prud’homme D, Pouliot MC, Tremblay A, Bouchard C. 
Estimation of deep abdominal adipose-tissue accumulation from simple 
anthropometric measurements in men. Am J Clin Nutr. 1991;54(3): 
471–477.
 38. Haffner SM. Abdominal adiposity and cardiometabolic risk: do we have 
all the answers? Am J Med. 2007;120(9 Suppl 1):S10–S16; discussion 
S16–S17.
 39. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. 
Nature. 2006;444(7121):881–887.
 40. Kemmler W, Teschler M, Weißenfels A, et al. Effects of whole-body 
electromyostimulation versus high-intensity resistance exercise on body 
composition and strength: a randomized controlled study. Evid Based 
Complement Alternat Med. 2016;2016:9236809.
 41. Kemmler W, von Stengel S, Engelke K, Sieber C, Freiberger E. Preva-
lence of sarcopenic obesity in Germany using established definitions: 
baseline data of the FORMOsA study. Osteoporos Int. 2016;27(1): 
275–281.
 42. Clark DO. Physical activity and its correlates among urban primary 
care patients aged 55 years or older. J Gerontol B Psychol Sci Soc Sci. 
1999;54(1):S41–S48.
 43. Schafer I, von Leitner EC, Schon G, et al. Multimorbidity patterns in 
the elderly: a new approach of disease clustering identifies complex 
interrelations between chronic conditions. PLoS One. 2010;5(12): 
e15941.
 44. McAuley E, Konopack JF, Motl RW, Rosengren K, Morris KS. Measur-
ing disability and function in older women: psychometric properties of 
the late-life function and disability instrument. J Gerontol A Biol Sci 
Med Sci. 2005;60(7):901–909.
 45. Dias N, Kempen GI, Todd CJ, et al. [The German version of the Falls 
Efficacy Scale-International Version (FES-I)]. Z Gerontol Geriatr. 
2006;39(4):297–300.
 
Cl
in
ica
l I
nt
er
ve
nt
io
ns
 in
 A
gi
ng
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
2.
18
7.
19
5.
17
 o
n 
20
-J
ul
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical Interventions in Aging
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/clinical-interventions-in-aging-journal
Clinical Interventions in Aging is an international, peer-reviewed journal 
focusing on evidence-based reports on the value or lack thereof of treatments 
intended to prevent or delay the onset of maladaptive correlates of aging 
in human beings. This journal is indexed on PubMed Central, MedLine, 
CAS, Scopus and the Elsevier Bibliographic databases. The manuscript 
management system is completely online and includes a very quick and fair 
peer-review system, which is all easy to use. Visit http://www.dovepress.
com/testimonials.php to read real quotes from published authors.
Clinical Interventions in Aging 2016:11submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
1706
Wittmann et al
 
Cl
in
ica
l I
nt
er
ve
nt
io
ns
 in
 A
gi
ng
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
2.
18
7.
19
5.
17
 o
n 
20
-J
ul
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
